Thursday, May 1, 2014
its Center for Regenerative Medicine having produced only one program ready for
clinical testing in the last four years, the NIH is rethinking its strategy for translating stem cell
therapies. When the NIH holds a stem cell workshop next month to map out its
path forward, many stakeholders hope the message will be that the NIH should
focus less on drug development and more on standardizing procedures and
has joined The New York Stem Cell Foundation (NYSCF) as VP of regenerative medicine-told SciBX that
the time is ripe for re-examining what roles the NIH, not-for-profit organizations,
academia and industry should play in the field.
companies have adopted various stem cell technologies in their screening
efforts, few have gone down the therapeutic path. According to Solomon, the NIH
should help solve logistical problems in translating innovations to the clinic,
whereas not-for-profit organizations should focus on derisking early stage
Fishburn, C.S. SciBX
Published online May 1, 2014
1. de Peppo, G.M. et al. Proc. Natl. Acad. Sci. USA 110, 8680-8685 (2013)
2. Fishburn, C.S. SciBX 7(8);
Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass.
California Institute for Regenerative Medicine, San Francisco, Calif.
Capricor Therapeutics Inc. (OTCQB:CAPR), Beverly Hills, Calif.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London,
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
Institutes of Health,
NeoStem Inc. (NASDAQ:NBS), New York, N.Y.
The New York Stem Cell Foundation, New York, N.Y.
Sangamo BioSciences Inc. (NASDAQ:SGMO), Richmond, Calif.